Table 1 Characteristics of study participants

Sex, Male/Female

11/15

10/13

10/13

12/12

Age, years

19.6*

(18.2;21.2)

19.1**

(18.3;22.4)

20.2

(18.6;23.3)

20.5

(18.3;23.8)

Weight, kg M/F

69.6/61.5

(48;109.9)/(44.5;88)

68/59.2

(55;85.5)/(44;72.4)

75.7/59

(62;89)/(48;106)

71.8/ 62

(56.5;117.4)/(44.8;112)

Length, cm M/F

175/166

(155;192)/(155;173)

182/165

(169;192)/ (152;173)

174/168

(164;182)/(150;176)

180/167

(168;194)/(151;190)

BMI, m/kg² M/F

20/22

(18;30)/(18;32)

20/ 21

(17;28)/(17;28)

24/21

(21;29)/(18;34)

21.5/22

(20;33)/(18;38)

FeNO, ppb

14.9

(9.2;22.2)

13.1

(11;19.8)

31.4**

(11.6;49.2)

10.9

(9.7;17.1)

Positive Phadiatop

3 (12)

8 (35)

23 (100)

0

Blood Eosinophils 1 × 10²/μL

0.1

(0.0;0.3)

0.0

(0.0;0.2)

0.3***

(0.0;0.7)

0.0

(0.0;0.5)

CRP, mg/L

0.35

(0;2.1)

0.32

(0;1.3)

0.46

(0;7.6)

0.34

(0;7.7)

Alpha-1 antitrypsin g/L

1.4

(0.8;1.7)

1.3

(1.0;1.7)

1.4

(1.1;1.8)

1.4

(1.1;1.9)

Antidepressant medication

1 (3.8)

2 (8.7)

2 (8.7)

1 (4.1)

ADHD/ADD medication

3 (11.5)

3 (13)

0

1 (4.1)